A PHASE 2, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE BLIND PROOF-OF-CONCEPT STUDY OF THE EFFICACY AND SAFETY OF PF-02545920 IN SUBJECTS WITH HUNTINGTON’S DISEASE

Update Il y a 4 ans
Reference: EUCTR2014-001291-56

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

• To assess the efficacy of 26-week oral daily dosing with PF-02545920 on motor function in subjects with HD.


Inclusion criteria

  • Huntington's disease